Publications by authors named "Ned H Latham"

Article Synopsis
  • The systematic review examines how different testing frequencies for hepatitis C virus (HCV) reinfection among key populations can impact detection and prevention of ongoing transmission.
  • It analyzed data from 41 studies, finding an overall HCV reinfection rate of 4.13 per 100 person-years, with men who have sex with men (MSM) experiencing the highest rates.
  • Results suggest that shorter testing intervals (≤6 months) may lead to higher detection rates of reinfections, emphasizing the need for more frequent testing to help in HCV elimination efforts.
View Article and Find Full Text PDF

We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat. Treatment rates by race/ethnicity were 38.

View Article and Find Full Text PDF
Article Synopsis
  • Direct-acting antivirals (DAAs) are primarily approved for chronic HCV, creating a challenge for treating recently acquired HCV due to limited access to these treatments.
  • A systematic review analyzed data from various studies on immediate DAA treatment in high-risk populations, finding a remarkable 95.9% success rate in achieving sustained virological response (SVR12).
  • Results indicated that immediate treatment resulted in high cure rates and few serious adverse events, suggesting that early intervention for recently acquired HCV is beneficial and safe.
View Article and Find Full Text PDF

Background And Aims: Direct-acting antivirals (DAAs) are highly effective in treating hepatitis C. However, there is concern that cure rates may be lower, and reinfection rates higher, among people who inject drugs. We conducted a systematic review of treatment outcomes achieved with DAAs in  people who inject drugs (PWID).

View Article and Find Full Text PDF

A barrier to hepatitis C treatment for people who inject drugs (PWID) is needing to attend multiple appointments for diagnosis. Point-of-care hepatitis C tests provide results within 20 to 105 minutes and can be offered opportunistically in nonclinical settings such as needle syringe programmes. In this nested qualitative study, we explored the acceptability of point-of-care testing for PWID.

View Article and Find Full Text PDF